Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences is poised for success due to its focused pipeline of neurodegenerative and neurodevelopmental disease treatments, which have shown promising results and high potential for addressing unmet needs. The company has continued to engage with regulators in both the US and EU, providing additional data and clarifying its regulatory pathway, while maintaining a strong dialogue with European regulators. The strategic decision to withdraw its application in Europe demonstrates management's commitment to strengthening its data package and approaching regulators from a more informed standpoint. With a diverse and innovative pipeline and a strategic approach to regulatory engagement, Anavex has the potential for significant long-term growth.

Bears say

Anavex Life Sciences is facing a setback with the withdrawal of its EU marketing application for blarcamesine in early Alzheimer's disease due to negative feedback from the EMA. With this strategic reset, the company plans to incorporate additional data and resubmit the application in the future. However, its ongoing regulatory engagement in the US and upcoming data disclosures in Alzheimer's disease and other indications show potential for future growth.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.